Australia Continuous Glucose Monitoring Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Australia Continuous Glucose Monitoring Market Trends and Insights

Rapidly Increasing Diabetes Prevalence

Australia’s diagnosed diabetes population rose to 1.5 million adults in 2024, equal to 6.6% of residents, up from 5.1% a decade earlier. Type 2 diabetes represents 1.2 million of these cases, yet full NDSS CGM subsidies still apply only to 130,000 Type 1 patients, creating a gap that policy makers are addressing. Indigenous Australians face diabetes rates three times the national average, and the Waminda pilot showed that 18 of 25 Aboriginal women achieved glycemic improvement using CGM plus group visits, with 7 attaining remission^{[2]Source: ABC News, “Aboriginal Women Reverse Type 2 Diabetes,” abc.net.au}. Parliamentary committees are therefore recommending subsidy expansion to high-risk insulin-dependent Type 2 and gestational cohorts, a step that could double the eligible patient pool by 2027. Employers in mining and resources are also piloting on-site CGM programs that cut high-risk worker counts by more than half, indicating commercial willingness to fill coverage gaps.

Advances in CGM Sensor Technology

Factory-calibrated sensors with mean absolute relative difference (MARD) below 10% have become the country standard, removing the need for finger-stick confirmation. Abbott’s FreeStyle Libre 3 posts a 7.9% MARD, while Dexcom G7 records 8.2% overall and 8.6% in pediatric users, comfortably inside Therapeutic Goods Administration non-adjunctive dosing criteria. Wear time now extends to 14 days, halving annual sensor counts and supporting adherence. Real-time Bluetooth feeds to smartphones enable predictive alerts and caregiver sharing, features that drive uptake in children and older adults. Medtronic’s Simplera all-in-one disposable sensor, launched globally in 2024, promises easier insertion and lower cost once TGA approval is secured. These advances collectively keep Australia continuous glucose monitoring market growth on a steep trajectory.

Expansion of NDSS Reimbursement Policies

The NDSS expanded coverage in May 2024 to every Type 1 patient, eliminating prior age caps and unlocking roughly 80,000 adults who had self-funded or skipped CGM. Dexcom G7 gained listing in March 2025, followed by Abbott’s Libre 2 Plus in April 2025, increasing product choice and applying price pressure. A parliamentary inquiry has urged further extension to insulin-dependent Type 2, gestational, and pancreatogenic diabetes, potentially adding 200,000 users by 2027 if adopted. Pediatric experience shows that adoption can increase from 5% to 79% within two years once cost barriers are removed, indicating a similar surge in adult adoption is feasible. TGA accuracy standards filter entrants, ensuring that only four qualified platforms currently benefit from an NDSS listing, which sustains product quality but limits supply diversity.

Integration with Hybrid Closed-Loop Insulin Systems

Hybrid closed-loop platforms adjust basal insulin in real time, raising the performance bar for sensors and creating durable demand for compatible transmitters. Insulet’s tubeless Omnipod 5 gained Pharmaceutical Benefits Scheme subsidy in July 2024, targeting tech-savvy Type 1 adults who favor discretion. Medtronic’s MiniMed 780G and Tandem’s t:slim X2 with Control-IQ are widening footprints in urban centers as clinicians report 70–75% time-in-range versus 50–60% for conventional therapy. Despite only 9% of adults using automated delivery in 2024, falling hardware costs and broader reimbursement are expected to accelerate penetration. Each system relies on proprietary sensor-transmitter links, setting off refresh cycles that benefit device makers and underpin premium pricing.

High Device and Consumable Cost

Unsubsidized Australians face annual CGM bills of AUD 3,000–5,000 (USD 1,980–3,300), confining uptake among 1.2 million Type 2 patients to under 5%. Even with NDSS support, transmitters and app fees can top AUD 500 (USD 330) yearly, burdening pensioners and low-income households. Abbott, Dexcom, and Medtronic dominate supply, limiting price competition, while parallel-import rules block cheaper overseas sourcing. Some employers offset costs through wellness schemes, but coverage remains inconsistent. NDSS distribution tenders also force suppliers to maintain temperature-controlled networks across a vast continent, adding 15–20% to logistics expenses and constraining aggressive price cuts.

Logistics Barriers to Serve Remote Regions

Roughly 30% of Australia lies beyond next-day courier service, complicating cold-chain delivery for temperature-sensitive sensors. Shipments to Indigenous communities can take up to 10 days, risking accuracy loss from heat exposure. Limited mobile coverage hampers real-time data transmission, and digital-literacy gaps mean some users lack compatible smartphones. The NDSS tender now mandates 1800 technical helplines and end-to-end order tracking, but few carriers offer cost-effective depot coverage in remote areas. Scaling proven pilots such as Waminda requires trained community health workers and culturally tailored materials, which are still scarce outside major cities.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Component: Sensor Dominance Sustains Revenue Leadership

Sensors generated 82.28% of Australia continuous glucose monitoring market revenue in 2025, and the segment is projected to maintain a double-digit trajectory as NDSS eligibility expands and factory-calibrated 14-day wear becomes the norm. Abbott’s Libre 3 and Dexcom G7 both pair smaller footprints with rapid 30-minute warmup, encouraging upgrades that buoy average selling prices even as unit counts decline. Australia continuous glucose monitoring market size for sensors is forecast to climb to USD 365.9 million in 2031, implying a 16.02% CAGR alongside steady subsidy inflows.

Durables—transmitters and receivers—represented the remaining 17.72% in 2025, yet they are forecast to outpace sensors at 17.05% CAGR, reaching USD 82.18 million by 2031 as hybrid closed-loop systems create mandatory hardware refresh cycles. Transmitter evolution toward Bluetooth Low Energy now extends battery life to three months, while smartphone apps are cannibalizing standalone receivers, leaving a niche among seniors and remote users who lack smartphones. Medtronic’s Simplera could disrupt segment boundaries by integrating transmitter elements into the disposable sensor if TGA approval arrives in 2026, potentially reshaping Australia continuous glucose monitoring market share dynamics among incumbents.

By Demography: Pediatric Growth Outstrips Adult Base

Adults constituted 64.38% of the user base in 2025, largely because historical NDSS rules favored children under 21. Nevertheless, pediatric uptake is advancing at 16.73% through 2031, driven by caregiver demand for remote alerts and clinical evidence showing 0.5–0.8% HbA1c reductions and 40% fewer severe hypoglycemia events. Australia continuous glucose monitoring market size for pediatric patients is on track to reach USD 174.58 million by 2031, closing the gap with adult spending.

Adult adoption widened sharply after the 2024 subsidy extension, with smartphone-centric platforms such as Dexcom G7 and Libre 3 resonating among the 18–35 segment. Older adults remain partial to dedicated receivers due to lower smartphone use. Indigenous programs that pair CGM with culturally adapted coaching are demonstrating meaningful HbA1c cuts, hinting at further upside in both adult and pediatric Indigenous cohorts if reimbursements broaden.

By End User: Hospitals Accelerate from a Smaller Base

Home and personal settings produced 73.62% of revenue in 2025 as diabetes self-management dominated purchasing decisions. Australia continuous glucose monitoring market share for hospitals is, however, climbing off a low base, with 16.89% CAGR expected through 2031 as inpatient protocols mandate continuous monitoring for surgical candidates and steroid-treated patients. Royal Melbourne Hospital cut mean length of stay by 1.2 days after integrating CGM dashboards into electronic medical records, illustrating economic payback for institutions.

The home channel benefits from NDSS subsidies that reimburse personal devices but not hospital stock, yet clinics remain critical for onboarding and periodic retraining. Corporate wellness pilots among FIFO workforces represent an emerging hybrid category where employers finance devices but users manage them independently on site, adding nuance to end-user segmentation. As hybrid closed-loop pumps become mainstream, hospitals are expected to serve as initiation hubs even while long-term wear occurs at home, supporting parallel growth across both channels.

Geography Analysis

Eastern seaboard cities—Sydney, Melbourne, and Brisbane—house more than 50% of the nation’s 1.5 million diabetes cases and account for a similar share of CGM revenue thanks to dense endocrinology networks and same-day NDSS pharmacy fulfillment. Urban clinics report waiting lists of six to eight weeks for CGM starts, a backlog that underscores continuing demand momentum. Regional centers such as Newcastle, Wollongong, Geelong, and the Gold Coast leverage telehealth links to metropolitan specialists, sustaining mid-teen growth without proportional specialist headcount.

Remote and very remote areas, covering 30% of land but only 3% of residents, struggle with 5–10-day sensor delivery lags and patchy mobile coverage that compromise real-time alerts. Indigenous prevalence three times higher than the national norm magnifies the public-health imperative. Successful pilots like Waminda in Nowra are prompting state funding for scaled deployments in Alice Springs, Broome, and Cairns, although equipment transport and cultural-competency training remain bottlenecks

Regulatory Landscape

In Australia, continuous glucose monitoring (CGM) systems are regulated by the Therapeutic Goods Administration (TGA) as medical devices and must be included on the Australian Register of Therapeutic Goods (ARTG) prior to supply, with CGM listings visible on the ARTG (for example, ARTG entries such as 496627 and 464033). Recent regulatory emphasis also extends to software that is integral to device performance (Software as a Medical Device), which makes change management for CGM apps and algorithm updates a practical compliance consideration for suppliers, alongside device performance and labeling requirements.

On access and reimbursement, the National Diabetes Services Scheme (NDSS) is the core channel shaping demand through defined eligibility and distribution rules, including health-professional certification and fulfillment via NDSS Access Points (commonly community pharmacies) under established access-point procedures. In parallel, the TGA introduced the Therapeutic Goods (Restricted Representations - Diabetes Devices Permission 2026), setting updated conditions for advertising diabetes devices and influencing how CGM suppliers communicate claims to consumers while remaining within the restricted-representation framework.

Market Opportunities and Future Outlook

NDSS subsidy settings create a defined pathway to broaden CGM utilization within already-eligible cohorts and to improve conversion from finger-stick testing, because access is operationalized through authorized health-professional certification and community-pharmacy NDSS Access Points. The May 2024 NDSS expansion to all people with type 1 diabetes, followed by product listings such as Dexcom G7 (March 2025) and Abbott Libre 2 Plus (April 2025), has also increased on-subsidy choice and supports switching and upgrade cycles, rather than single-platform lock-in.

A second whitespace is affordability-led offerings and funding submissions aimed at insulin-dependent type 2 diabetes and other high-need groups, where self-funding remains a barrier. Market activity in 2026 reflects this: the Office of Health Technology Assessment consultation closed on 12 June 2026 for MSAC Application 1785 (resubmission) seeking NDSS funding for Dexcom ONE+ for people with insulin-dependent type 2 diabetes, while Abbott and AMSL resubmissions were scheduled for re-evaluation at the July 2026 MSAC meeting. Alongside funding pathways, manufacturers continue to refresh portfolios to reduce friction and improve performance, including Abbott introducing FreeStyle Libre 3 Plus in Australia in April 2026. Hospital protocol standardization and hybrid closed-loop pump ecosystems also sustain demand for compatible sensors and related durable hardware.